Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | GRM5 | P41594 | 3/20 | 0.55 |
| ▸ | CLPP | Q16740 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3137394 | 1.00 | L3MBTL1 (0.60) | L3MBTL1RAB9AGRM5CLPPATM | |
| SCHEMBL3130199 | 0.94 | L3MBTL1 (0.63) | L3MBTL1RAB9AGRM5CLPPATM | |
| SCHEMBL3140639 | 0.94 | GRM5 (0.63) | L3MBTL1RAB9AGRM5CLPPATM | |
| SCHEMBL3130211 | 0.94 | L3MBTL1 (0.63) | L3MBTL1RAB9AGRM5CLPPATM | |
| SCHEMBL3146200 | 0.94 | GRM5 (0.63) | L3MBTL1RAB9AGRM5CLPPATM | |
| SCHEMBL3137416 | 0.93 | L3MBTL1 (0.69) | L3MBTL1RAB9AGRM5CLPPMEN1 | |
| SCHEMBL3137399 | 0.93 | L3MBTL1 (0.69) | L3MBTL1RAB9AGRM5CLPPMEN1 | |
| SCHEMBL3141171 | 0.92 | L3MBTL1 (0.63) | L3MBTL1RAB9AGRM5CLPPATM | |
| SCHEMBL3141179 | 0.92 | L3MBTL1 (0.63) | L3MBTL1RAB9AGRM5CLPPATM | |
| SCHEMBL3133519 | 0.91 | L3MBTL1 (0.59) | L3MBTL1RAB9AGRM5CLPPATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004284-A1 | Novel Heterocyclic Compounds as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | ADDEX PHARMA SA (CH) | 2010-01-07 | — | — | US | claimed |
| EP-1896464-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharma SA (CH) | 2008-03-12 | — | — | EP | claimed |
| WO-2006129199-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2006-12-07 | — | — | WO | claimed |
| US-20100004284-A1 | Novel Heterocyclic Compounds as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | ADDEX PHARMA SA (CH) | 2010-01-07 | — | — | US | disclosed |
| EP-1896464-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharma SA (CH) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006129199-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004284-A1 | Novel Heterocyclic Compounds as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | GRM5, GRM1, GRIK5 | L3MBTL1 3297/4885RAB9A 1083/4885GRM5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.